Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822573 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil
A Phase 3 study of Cognitive Dysfunction and Memory Impairment, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT02822573 is a Phase 3 study of Cognitive Dysfunction and Memory Impairment that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 276 participants, below the 1,987-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 1 state.
The verdict
NCT02822573, a Phase 3 study of Cognitive Dysfunction and Memory Impairment, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to compare the safety and effects of donepezil (Aricept) for patients reporting cognitive or memory issues after receiving chemotherapy for breast cancer. Patients will receive either donepezil or placebo for 24 weeks. The primary objective is to see if memory improves with the use of donepezil during the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Donepezil 5 mg
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Kaiser Permanente-Fontana - Fontana
- Kaiser Permanente-Fremont - Fremont
- Fresno Cancer Center - Fresno
- Kaiser Permanente-Fresno - Fresno
- Kaiser Permanente - Harbor City - Harbor City
- Kaiser Permanente-Irvine - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Kaiser Permanente West Los Angeles - Los Angeles
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- Kaiser Permanente-Ontario - Ontario
- Kaiser Permanente - Panorama City - Panorama City
- Kaiser Permanente-Rancho Cordova Cancer Center - Rancho Cordova
- Kaiser Permanente-Richmond - Richmond
- Kaiser Permanente-Riverside - Riverside
- Kaiser Permanente-Roseville - Roseville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02822573
The ClinicalTrials.gov registry entry for NCT02822573 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,987-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (86% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cognitive Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02822573 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02822573 about?
NCT02822573 is a clinical study titled "Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil". This study is to compare the safety and effects of donepezil (Aricept) for patients reporting cognitive or memory issues after receiving chemotherapy for breast cancer. Patients will receive either donepezil or placebo for 24 weeks. The primary objective is to see if memory improves with the use of ...
What is the current status of trial NCT02822573?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2017-05-30. Estimated completion is 2022-07-29.
What conditions does trial NCT02822573 study?
This clinical trial studies the following conditions: Cognitive Dysfunction, Memory Impairment.
What interventions are being tested in trial NCT02822573?
The interventions under investigation include: Placebo (DRUG), Donepezil 5 mg (DRUG).
Who is sponsoring clinical trial NCT02822573?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02822573 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Surviving Daily Life
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
RECRUITING · NA
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.